Invokana

Chemical Namecanagliflozin
Dosage FormTablet (oral; 100 mg, 300 mg)
Drug ClassInhibitors
SystemEndocrine, Cardiovascular
CompanyJanssen Pharmaceuticals
Approval Year2013

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • Indicated to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria.
Last updated on 7/6/2022

More on this drug: Clinical Trials

Document TitleYearSource
Invokana (canagliflozin) Prescribing Information.2020Janssen Pharmaceuticals, Inc., Titusville NJ
Document TitleYearSource
Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials.2022Advances in Therapy
Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. 2022Frontiers in Endocrinology
Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTs.2022American Journal of Cardiovascular Drugs
Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis. 2022Journal of Diabetes Research
Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis.2022Canadian Journal of Diabetes
Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis.2022Journal of Family Medicine and Primary Care
Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. 2021Current Diabetes Review
Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes.2021The Journal of Endocrinology & Metabolism
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients.2021Medicine
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials.2021Heart Rhythm
Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic literature review and network meta-analysis.2021Diabetes Therapy
Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.2021Oman Medical Journal
Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta- analysis of randomized placebo-controlled trials.2021Frontiers in Endocrinology
Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in adults with type 2 diabetes: a Bayesian meta-analysis and meta-regression.2021Journal of the American Heart Association
High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials.2021Diabetes, Obesity and Metabolism
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.2021Heart Failure Reviews
Comparative efficacy of glucose-lowering medications on bodyweight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.2021Diabetes, Obesity and Metabolism
Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators.2021Journal of Clinical Medicine
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials.2021Primary Care Diabetes
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases.2021Medicine
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. 2020Annals of Internal Medicine
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.2020Heart Failure Reviews
Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials. 2020Cardiology in Review
Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis.2020Medical Sciences
Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials. 2020Diabetes Research and Clinical Practice
Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis.2019Diabetes Therapy
Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials .2019Diabetes Research and Clinical Practice
Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.2018Journal of Pharmacy and Pharmaceutical Sciences
Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials. 2018Diabetes Research and Clinical Practice
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. 2018Current Medical Research and Opinion
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis.2018Saudi Journal of Biological Sciences
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2017Diabetologia
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta‐ analysis. 2017Diabetes Metabolism Research and Reviews
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials.2017BMC Pharmacology and Toxicology
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials.2017Diabetes, Obesity and Metabolism
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. 2017Diabetes, Obesity and Metabolism

Have we missed a study, or would you like to comment on a study?